AU596611B2 - New quinazoline derivatives and a process for their production - Google Patents

New quinazoline derivatives and a process for their production Download PDF

Info

Publication number
AU596611B2
AU596611B2 AU63589/86A AU6358986A AU596611B2 AU 596611 B2 AU596611 B2 AU 596611B2 AU 63589/86 A AU63589/86 A AU 63589/86A AU 6358986 A AU6358986 A AU 6358986A AU 596611 B2 AU596611 B2 AU 596611B2
Authority
AU
Australia
Prior art keywords
alkyl
nujol
compound
ethyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63589/86A
Other languages
English (en)
Other versions
AU6358986A (en
Inventor
Yukihisa Baba
Masashi Hashimoto
Yoshikuni Ito
Chiyoshi Kasahara
Takayuki Namiki
Teruo Oku
Kozo Sawada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of AU6358986A publication Critical patent/AU6358986A/en
Application granted granted Critical
Publication of AU596611B2 publication Critical patent/AU596611B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU63589/86A 1985-10-07 1986-10-06 New quinazoline derivatives and a process for their production Ceased AU596611B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8524663 1985-10-07
GB858524663A GB8524663D0 (en) 1985-10-07 1985-10-07 Quinazoline derivatives

Publications (2)

Publication Number Publication Date
AU6358986A AU6358986A (en) 1987-04-09
AU596611B2 true AU596611B2 (en) 1990-05-10

Family

ID=10586291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63589/86A Ceased AU596611B2 (en) 1985-10-07 1986-10-06 New quinazoline derivatives and a process for their production

Country Status (23)

Country Link
US (2) US4734419A (enExample)
EP (1) EP0218999B1 (enExample)
JP (3) JPS6296476A (enExample)
KR (1) KR940007270B1 (enExample)
CN (1) CN1017242B (enExample)
AT (1) ATE60761T1 (enExample)
AU (1) AU596611B2 (enExample)
CA (1) CA1289139C (enExample)
DE (1) DE3677452D1 (enExample)
DK (1) DK158838C (enExample)
ES (1) ES2021266B3 (enExample)
FI (1) FI90234C (enExample)
GB (1) GB8524663D0 (enExample)
GR (1) GR3001502T3 (enExample)
HK (1) HK6993A (enExample)
HU (1) HU196972B (enExample)
IE (1) IE59309B1 (enExample)
IL (1) IL80213A (enExample)
NO (1) NO171785C (enExample)
SG (1) SG112092G (enExample)
SU (1) SU1588283A3 (enExample)
UA (1) UA5562A1 (enExample)
ZA (1) ZA867043B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU615932B2 (en) * 1987-07-29 1991-10-17 Fujisawa Pharmaceutical Co., Ltd. Uricosuric composition
AU622638B2 (en) * 1988-02-29 1992-04-16 Fujisawa Pharmaceutical Co., Ltd. Diuretic or antihypertensive composition

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
WO1988001270A1 (en) * 1986-08-21 1988-02-25 Pfizer Inc. Pyridopyrimidinediones
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US4898867A (en) * 1987-09-16 1990-02-06 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivaties as aldose-reductase inhibitors
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
EP0847382B1 (de) * 1995-08-31 2000-12-20 Clariant GmbH Monoester der carboxymethylenanthranilsäuren und verfahren zu ihrer herstellung
DE19532052C2 (de) * 1995-08-31 1998-11-19 Clariant Gmbh Verfahren zur Herstellung von Chinazolinderivaten
CA2193932C (en) * 1995-12-26 2001-08-21 Shinji Nishii Process for producing isatoic anhydrides
WO1997024335A1 (en) * 1995-12-28 1997-07-10 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
DE69701647T2 (de) * 1996-02-01 2000-09-07 Sumitomo Chemical Co., Ltd. Verfahren zur Herstellung von Dioxochinazolinen
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
ES2363230T3 (es) * 1997-04-15 2011-07-27 Csir Métodos no terapéuticos para suprimir el apetito.
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
TR200002209T2 (tr) 1998-01-30 2000-11-21 R-Tech Ueno, Ltd. Oftalmik bileşim.
WO2000043015A1 (fr) * 1999-01-25 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Gouttes ophtalmologiques
BR0005010A (pt) 1999-02-18 2002-03-19 R Tech Ueno Ltd Composição para tratamento de distúrbios de secreção externa exceto a hipolacrimação e seu uso
AU2830700A (en) * 1999-03-09 2000-09-28 Fujisawa Pharmaceutical Co., Ltd. Process for producing quinazoline derivative or salt thereof
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
CN1477976A (zh) 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与醛糖还原酶抑制剂的组合
WO2002098462A1 (en) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
JP2006508030A (ja) * 2002-05-09 2006-03-09 サイトキネティクス・インコーポレーテッド ピリミジノン化合物、組成物および方法
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004026226A2 (en) * 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7041676B2 (en) * 2002-06-14 2006-05-09 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US20040048853A1 (en) * 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1692112A4 (en) * 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2044002B1 (en) * 2006-07-19 2014-04-16 E.I. Du Pont De Nemours And Company Process for making 3-substituted 2-amino-5-halobenzamides
WO2008110551A1 (en) 2007-03-12 2008-09-18 Zadec Aps An anti-diabetic extract of rooibos
WO2008118844A1 (en) 2007-03-23 2008-10-02 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
CN101784515A (zh) * 2007-08-03 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN102219759B (zh) * 2010-04-16 2013-07-24 中国科学院上海药物研究所 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
WO2012088525A2 (en) 2010-12-23 2012-06-28 The Board Of Regents Of The University Of Texas System Methods for treating copd
AU2014262636A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
JP6434498B2 (ja) 2013-05-10 2018-12-05 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
WO2014182951A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
CN111499616B (zh) * 2020-05-07 2022-07-22 盐城工学院 一种芳杂环取代的喹唑啉酮衍生物及其合成方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405623A (en) * 1980-05-15 1983-09-20 Masayuki Ishikawa Quinazolinde-dione compounds, process for production thereof and pharmaceutical use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016166A (en) * 1973-12-14 1977-04-05 Hisamitsu Pharmaceutical Co., Inc. 1-Nitrophenylquinazoline-2,4(1H,3H)-diones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
DE3172006D1 (en) * 1980-05-22 1985-10-03 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DD232702A1 (de) * 1982-09-20 1986-02-05 Adw Ddr Verfahren zur herstellung von 1,2,3,4-tetrahydrochinazolin-2,4-dion-essigsaeuren, deren salzen und estern
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
JPS59186963A (ja) * 1983-04-08 1984-10-23 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405623A (en) * 1980-05-15 1983-09-20 Masayuki Ishikawa Quinazolinde-dione compounds, process for production thereof and pharmaceutical use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU615932B2 (en) * 1987-07-29 1991-10-17 Fujisawa Pharmaceutical Co., Ltd. Uricosuric composition
AU622638B2 (en) * 1988-02-29 1992-04-16 Fujisawa Pharmaceutical Co., Ltd. Diuretic or antihypertensive composition

Also Published As

Publication number Publication date
JPH01131164A (ja) 1989-05-24
FI90234C (fi) 1994-01-10
HU196972B (en) 1989-02-28
ATE60761T1 (de) 1991-02-15
US4734419A (en) 1988-03-29
AU6358986A (en) 1987-04-09
CN86106984A (zh) 1987-05-20
FI863917L (fi) 1987-04-08
GB8524663D0 (en) 1985-11-13
NO171785C (no) 1993-05-05
EP0218999A2 (en) 1987-04-22
GR3001502T3 (en) 1992-11-23
NO863980D0 (no) 1986-10-06
DK158838B (da) 1990-07-23
CN1017242B (zh) 1992-07-01
CA1289139C (en) 1991-09-17
JPH05366B2 (enExample) 1993-01-05
SG112092G (en) 1992-12-24
IL80213A0 (en) 1987-01-30
IE59309B1 (en) 1994-02-09
JPS6296476A (ja) 1987-05-02
SU1588283A3 (ru) 1990-08-23
KR870003998A (ko) 1987-05-06
UA5562A1 (uk) 1994-12-28
DK459086A (da) 1987-04-08
ZA867043B (en) 1987-07-29
DK459086D0 (da) 1986-09-25
NO171785B (no) 1993-01-25
EP0218999B1 (en) 1991-02-06
US4883800A (en) 1989-11-28
EP0218999A3 (en) 1988-01-13
JPH01125322A (ja) 1989-05-17
FI863917A0 (fi) 1986-09-29
KR940007270B1 (en) 1994-08-12
JPH0482148B2 (enExample) 1992-12-25
HK6993A (en) 1993-02-05
HUT41747A (en) 1987-05-28
DE3677452D1 (de) 1991-03-14
JPH0794447B2 (ja) 1995-10-11
IL80213A (en) 1991-06-30
IE862520L (en) 1987-04-07
FI90234B (fi) 1993-09-30
ES2021266B3 (es) 1991-11-01
NO863980L (no) 1987-04-08
DK158838C (da) 1991-01-14

Similar Documents

Publication Publication Date Title
AU596611B2 (en) New quinazoline derivatives and a process for their production
FI114023B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten kinatsolinonien valmistamiseksi
CN110719902B (zh) Ssao抑制剂
CA2680789C (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US3702849A (en) 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters
FI112484B (fi) Menetelmä 2-(2-alkoksifenyyli)pyrido[3,2-d]pyrimidin-4(3H)-onijohdannaisten valmistamiseksi
EP0318225B1 (en) 6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents
NZ251804A (en) Aromatic quinazoline derivatives and medicaments
JPWO1997011941A1 (ja) キナゾリン誘導体およびその用途
JPH07165708A (ja) 二環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
NZ273073A (en) Bicyclic heterocyclic sulphonamide and sulphonic acid ester derivatives and pharmaceutical compositions thereof
JPH11504922A (ja) 蛋白チロシンキナーゼ媒介細胞増殖を抑制するためのピリド［２，３−ｄ］ピリミジン類
US4782055A (en) Imidazopyridine compounds useful in the treatment of ulcers
IL98542A (en) Benzoquinazoline derivatives their preparation and pharmaceutical compositions containing them
CZ20031334A3 (cs) Isochinolinové deriváty a jejich použití jako inhibitory
JPH01313469A (ja) キナゾリン、その製法及びこれを含有する抗腫瘍作用を有する製薬学的組成物
EP0901789B1 (en) Method of treating tourette's syndrome
WO2013030358A1 (en) Glycine b antagonists
EP0901473B1 (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the novel compounds
JPH01157955A (ja) 新規複素環誘導体およびその製造法
JPH0558434B2 (enExample)
CA2100164A1 (en) 2,4-dioxo-pyrido[2,3-d]pyrimidine-3-acetic acids and esters and salts thereof

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired